News
SRZN
32.18
+0.63%
0.20
Weekly Report: what happened at SRZN last week (0921-0925)?
Weekly Report · 2d ago
Surrozen Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 5d ago
Surrozen Price Target Raised to $54.00/Share From $44.00 by HC Wainwright & Co.
Dow Jones · 5d ago
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Benzinga · 5d ago
HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54
Benzinga · 5d ago
Surrozen price target raised to $54 from $44 at H.C. Wainwright
TipRanks · 5d ago
Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 6d ago
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Surrozen (SRZN) and aTyr Pharma (ATYR)
TipRanks · 6d ago
Dow Tumbles Over 100 Points; US Jobless Claims Fall to 197,000
Benzinga · 6d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 6d ago
Two new option listings and eight option delistings on September 21st
TipRanks · 09/21 12:35
Weekly Report: what happened at SRZN last week (0914-0918)?
Weekly Report · 09/21 09:31
Weekly Report: what happened at SRZN last week (0907-0911)?
Weekly Report · 09/14 09:33
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Surrozen (SRZN), Liquidia Technologies (LQDA) and Universal Health (UHS)
TipRanks · 09/09 09:50
Surrozen submits investigational new drug application for SZN-8141
TipRanks · 09/08 13:10
Surrozen Submits IND Application To FDA Seeking To Evaluate SZN-8141, Bifunctional Wnt Agonist And Vascular Endothelial Growth Factor Antagonist Antibody, For Treatment Of Diabetic Macular Edema
Benzinga · 09/08 12:32
Weekly Report: what happened at SRZN last week (0831-0904)?
Weekly Report · 09/07 09:30
Weekly Report: what happened at SRZN last week (0824-0828)?
Weekly Report · 08/31 09:33
More
Webull provides a variety of real-time SRZN stock news. You can receive the latest news about Surrozen Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRZN
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.